Q3 INTERIM REPORT July-Sept 2024
Read More
Mentice has received a €1,062,750 EUR order for simulation solutions from a top 20 global MedTech company
Read more

Mentice publishes the company’s interim report for the period January–June 2020

Thursday, August 13, 2020

Solid performance for the quarter and the first half of the year despite the effects of the pandemic
 

Second quarter 2020

  • Net sales amounted to 24.3 (32.4) MSEK.
  • Operating income for the period before depreciations (EBITDA) totalled -12.0 (-10.1) MSEK.
  • Net income for the period amounted to -11.1 (-10.8) MSEK.
  • Earnings per share (EPS) was -0.46 (-0.59) SEK.
  • Order intake amounted to 28.4 (34.9) MSEK.
  • Cash flow from operating activities totalled 15.2 (-0.8) MSEK.

January-June 2020

  • Net sales for the first half of the year amounted to 58.1 (59.8) MSEK.
  • Operating income for the first half of the year before depreciations (EBITDA) totalled
    -12.5 (-18.0) MSEK.
  • Net income for the first half of the year amounted to -16.1 (-19.4) MSEK.
  • Earnings per share (EPS) for the first half of the year was -0.67 (-1.30) SEK.
  • Order intake for the first half of the year amounted to 60.9 (60.0) MSEK.
  • Cash flow from operating activities for the first half of the year totalled 16.7 (-4.5) MSEK.

“Despite extremely difficult market conditions due to the Covid-19 pandemic, Mentice’s

performance during the second quarter has been solid, resulting in a strong first half-year

financial result. For the first half of the year, orders received were 1,6 % above the first half of

2019, while net sales were 2.9 % lower compared to the first six months of 2019,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for January–June 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on August 13, 2020 at 09:30 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations.

Please make sure to register at least a few minutes in advance.

 

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on August 13, 2020 08:30 CEST.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.

Q3 DELÅRSRAPPORT Juli-Sept 2024
Läs mer
Mentice får en order på simuleringslösningar värd €1,062,750 EUR från ett topp 20 globalt medtech bolag
Läs Mer

Mentice publishes the company’s interim report for the period January–June 2020

Thursday, August 13, 2020

Solid performance for the quarter and the first half of the year despite the effects of the pandemic
 

Second quarter 2020

  • Net sales amounted to 24.3 (32.4) MSEK.
  • Operating income for the period before depreciations (EBITDA) totalled -12.0 (-10.1) MSEK.
  • Net income for the period amounted to -11.1 (-10.8) MSEK.
  • Earnings per share (EPS) was -0.46 (-0.59) SEK.
  • Order intake amounted to 28.4 (34.9) MSEK.
  • Cash flow from operating activities totalled 15.2 (-0.8) MSEK.

January-June 2020

  • Net sales for the first half of the year amounted to 58.1 (59.8) MSEK.
  • Operating income for the first half of the year before depreciations (EBITDA) totalled
    -12.5 (-18.0) MSEK.
  • Net income for the first half of the year amounted to -16.1 (-19.4) MSEK.
  • Earnings per share (EPS) for the first half of the year was -0.67 (-1.30) SEK.
  • Order intake for the first half of the year amounted to 60.9 (60.0) MSEK.
  • Cash flow from operating activities for the first half of the year totalled 16.7 (-4.5) MSEK.

“Despite extremely difficult market conditions due to the Covid-19 pandemic, Mentice’s

performance during the second quarter has been solid, resulting in a strong first half-year

financial result. For the first half of the year, orders received were 1,6 % above the first half of

2019, while net sales were 2.9 % lower compared to the first six months of 2019,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for January–June 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on August 13, 2020 at 09:30 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations.

Please make sure to register at least a few minutes in advance.

 

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on August 13, 2020 08:30 CEST.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.